Darzalex sales exceed expectations in second quarter

Sales of Johnson & Johnson's drug Darzalex totaled USD 1.43bn in Q2, far surpassing analysts' expectations for the drug, which was originally developed by Genmab.

Photo: Tuala Hjarnø / Genmab / PR

At the half-way point of 2021, Genmab-developed drug Darzalex is close to achieving triple-blockbuster status, after a significant growth in sales compared to last year.

Johnson & Johnson report that sales of Darzalex in Q2 alone totaled USD 1.43bn, up from USD 901m for the same period last year. This brings the total sales for the first half of 2021 up to USD 2.8bn.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs